What are the precautions and contraindications of tranexamic acid and the price of the drug?

The precautions for (CYKLOKAPRON) mainly include the risk of thromboembolism, incorrect administration route leading to medication errors, seizures, allergic reactions, visual disturbances and dizziness. At the same time, tranexamic acid is contraindicated in patients with subarachnoid hemorrhage, patients with active intravascular coagulation and patients who are allergic to tranexamic acid or any component.

It is understood that the reference price range of tranexamic acid tablets is 500mg*100 tablets, which is between 500 and 600$.

About tranexamic acid

Tranexamic acid (TXA) is an important synthetic derivative that can inhibit fibrinolysis by blocking the lysine binding site on plasminogen and limit the activation of plasmin, thereby reducing bleeding. It is mostly used in clinical medicine. Compared with other known fibrinolytic agents, tranexamic acid has been proven to have the advantage of fewer side effects. It can usually be used for the treatment of dysfunctional uterine bleeding and chloasma, and has broad market application prospects.

Precautions for tranexamic acid

1. Risk of thromboembolism

CYKLOKAPRON is contraindicated in patients with active intravascular coagulation. Tranexamic acid is an antifibrinolytic drug and may increase the risk of thromboembolic events.

Action: Avoid coadministration of CYKLOKAPRON with prothrombotic medical products as the risk of thrombosis may be increased. These medications include, but are not limited to, factor IX complex concentrates, anti-inhibitor coagulant concentrates, and hormonal contraceptives.

2. Risk of medication errors caused by incorrect administration route

CYKLOKAPRON is for intravenous injection only. Serious adverse reactions, including seizures and cardiac arrhythmias, have occurred when CYKLOKAPRON was inadvertently administered intrathecally instead of intravenously.

Measures: Confirm the correct route of administration of CYKLOKAPRON and avoid confusion with other injections that may be administered at the same time as CYKLOKAPRON. Syringes containing CYKLOKAPRON should be clearly marked for intravenous administration.

3. Seizures

CYKLOKAPRON may cause epileptic seizures, including focal and generalized seizures.

Management measures: CYKLOKAPRON is not approved and is not recommended for axonal delivery. Consider dose reduction during surgery and dose adjustments in patients with clinical disease such as renal dysfunction. Monitor the patient closely during surgery. Consider electroencephalography (EEG) monitoring in patients with a history of seizures or who experience myoclonic movements, convulsions, or show evidence of focal epileptic seizures. If seizure occurs, stop taking CYKLOKAPRON.

4. Anaphylaxis

There have been cases of allergic reactions (including anaphylaxis) when using intravenous tranexamic acid.

Management: If a serious reaction occurs, discontinue treatment with CYKLOKAPRON, provide appropriate medical management, and do not restart treatment. CYKLOKAPRON is contraindicated in patients with a history of allergy to tranexamic acid.

5. Visual impairment

No retinal changes were observed in eye examinations of patients treated with tranexamic acid for up to 8 years.

Management measures: Patients whose treatment time is expected to exceed 3 months may consider regular ophthalmic monitoring, including visual acuity and optical coherence tomography. If you experience changes on your eye exam, stop taking CYKLOKAPRON.

6. Dizziness

CYKLOKAPRON may cause dizziness. Concomitant use of other medications that may cause dizziness may worsen this effect. Treatment: Advise patients to avoid driving or using machinery until they know how CYKLOKAPRON affects them.

For more information about tranexamic acid, please refer to: and other articles.

Contraindications of tranexamic acid

Contraindicated use of CYKLOKAPRON injection:

1. Patients with subarachnoid hemorrhage. Anecdotal experience suggests that CYKLOKAPRON may cause cerebral edema and cerebral infarction in such patients.

2. For patients with active intravascular coagulation.

3. Patients who are allergic to tranexamic acid or any ingredients.

The drug price of tranexamic acid

It is understood that the reference price range of tranexamic acid tablets is 500mg*100 tablets, which is between 500 and 600$.

At present, the drug has been launched in China and has been included in the medical insurance. Patients can go to hospitals and pharmacies to purchase the drug with a doctor's prescription, and can enjoy certain medical insurance discounts. However, more people choose to trust overseas medical service agencies to help them purchase tranexamic acid tablets, and the price is more affordable than domestic ones.

Recommended hot articles: